<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13604">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00385216</url>
  </required_header>
  <id_info>
    <org_study_id>AAAA6273</org_study_id>
    <nct_id>NCT00385216</nct_id>
  </id_info>
  <brief_title>Nicotine as an Adjuvant Analgesic for Third Molar Surgery</brief_title>
  <official_title>Effect of Nicotine on Pain After Third Molar Extraction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Third molar surgery is complicated by pain and swelling for several days after surgery.
      Non-steroidal antiinflammatory drugs have been useful in combination with opioids for
      treatment. Nicotine has antiinflammatory and pain relieving properties. We will use nicotine
      or placebo as a nasal spray before surgery to determine whether nicotine affects pain or
      inflammation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized double blind cross-over study. In each of two sittings, the third
      molars on one side of the mouth are removed. In one sitting the subject will receive a
      nicotine nasal spray (3mg) and in the other placebo. VAS and narcotic utilization will be
      compared within patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pain Reported by Patient</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain reported on the numerical rating scale for pain (NRS) with 0=no pain and 10=worst pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nausea</measure>
    <time_frame>5 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hydrocodone5 mg/Acetaminopgen 325 mg Use</measure>
    <time_frame>5 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>5 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Heart rate reported in beats per minute (BPM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>5 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Systolic blood pressure reported in Millimeters of Mercury (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>5 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Diastolic blood pressure reported in Millimeters of Mercury (mmHg)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Dental Crowding</condition>
  <arm_group>
    <arm_group_label>Nicotine nasal spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In one sitting the subject will receive a nicotine nasal spray, 3 mg, one application.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In one sitting the subject will receive a placebo nasal spray (0 mg), one application.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine</intervention_name>
    <description>Nicotine nasal spray 3mg x 1 before surgery</description>
    <arm_group_label>Nicotine nasal spray</arm_group_label>
    <other_name>Nasal spray, nicotine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo nasal spray 0mg x 1 before surgery</description>
    <arm_group_label>Placebo spray</arm_group_label>
    <other_name>Nasal spray, placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  over 18

          -  4 molars to be removed

        Exclusion Criteria:

          -  pregnant

          -  lactating

          -  chronic pain

          -  narcotic use

          -  asthma

          -  ex-smokers
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela Flood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <lastchanged_date>December 1, 2010</lastchanged_date>
  <firstreceived_date>October 5, 2006</firstreceived_date>
  <firstreceived_results_date>October 1, 2010</firstreceived_results_date>
  <responsible_party>
    <name_title>Pamela Flood</name_title>
    <organization>Columbia University</organization>
  </responsible_party>
  <keyword>Third Molar</keyword>
  <keyword>Pain</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nicotine Nasal Spray First, Then Placebo</title>
          <description>At the first intervention, the subject will receive a nicotine nasal spray, 3 mg, one application. At the second intervention, the subject will receive a placebo nasal spray, 0 mg, one application.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Spray First, Then Nicotine</title>
          <description>At the first intervention, the subject will receive a placebo nasal spray, 0 mg, one application. At the second intervention, the subject will receive a nicotine nasal spray, 3 mg, one application.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>The baseline characteristics for the entire study population are presented here. The nicotine and placebo study populations were identical.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="23" spread="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Reported by Patient</title>
        <description>Pain reported on the numerical rating scale for pain (NRS) with 0=no pain and 10=worst pain.</description>
        <time_frame>1 day</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Nasal Spray</title>
            <description>Nicotine nasal spray (3mg) was administered as 3 sprays to each nostril before surgery in either first intervention period or second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sterile saline placebo was administered as 3 sprays to each nostril before surgery in either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pain Reported by Patient</title>
            <description>Pain reported on the numerical rating scale for pain (NRS) with 0=no pain and 10=worst pain.</description>
            <units>Numeric Rating Scale (NRS)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.6" spread="0.5"/>
                  <measurement group_id="O2" value="2.9" spread="0.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nausea</title>
        <time_frame>5 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>hydrocodone5 mg/Acetaminopgen 325 mg Use</title>
        <time_frame>5 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate</title>
        <description>Heart rate reported in beats per minute (BPM)</description>
        <time_frame>5 days</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Nasal Spray</title>
            <description>Nicotine nasal spray (3mg) was administered as 3 sprays to each nostril before surgery in either first intervention period or second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sterile saline placebo was administered as 3 sprays to each nostril before surgery in either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Heart Rate</title>
            <description>Heart rate reported in beats per minute (BPM)</description>
            <units>Beats per minute (BPM)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="81" spread="15"/>
                  <measurement group_id="O2" value="76" spread="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure</title>
        <description>Systolic blood pressure reported in Millimeters of Mercury (mmHg)</description>
        <time_frame>5 days</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Nasal Spray</title>
            <description>Nicotine nasal spray (3mg) was administered as 3 sprays to each nostril before surgery in either first intervention period or second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sterile saline placebo was administered as 3 sprays to each nostril before surgery in either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Systolic Blood Pressure</title>
            <description>Systolic blood pressure reported in Millimeters of Mercury (mmHg)</description>
            <units>Millimeters of Mercury (mmHg)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="120" spread="11"/>
                  <measurement group_id="O2" value="121" spread="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure</title>
        <description>Diastolic blood pressure reported in Millimeters of Mercury (mmHg)</description>
        <time_frame>5 days</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Nasal Spray</title>
            <description>Nicotine nasal spray (3mg) was administered as 3 sprays to each nostril before surgery in either first intervention period or second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sterile saline placebo was administered as 3 sprays to each nostril before surgery in either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Diastolic Blood Pressure</title>
            <description>Diastolic blood pressure reported in Millimeters of Mercury (mmHg)</description>
            <units>Millimeters of Mercury (mmHg)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="77" spread="8"/>
                  <measurement group_id="O2" value="76" spread="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Nicotine Nasal Spray</title>
          <description>Nicotine nasal spray (3mg) was administered as 3 sprays to each nostril before surgery in either first intervention period or second intervention period.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Sterile saline nasal spray was administered as 3 sprays to each nostril before surgery in either first intervention period or second intervention period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a small study under typical clinical conditions.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pamela Flood, MD</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-305-2008</phone>
      <email>pdf3@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
